Free Trial
→ Your book attached (From Profits Run) (Ad)tc pixel
NASDAQ:NBIX

Neurocrine Biosciences Q3 2026 Earnings Date & Estimates

Neurocrine Biosciences logo
$135.13 -6.24 (-4.41%)
Closing price 04:00 PM Eastern
Extended Trading
$135.32 +0.19 (+0.14%)
As of 07:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Neurocrine Biosciences is estimated to report Q3 2026 earnings on Monday, November 2, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Neurocrine Biosciences in Q3 2026

Neurocrine Biosciences is expected to post earnings of $1.91 per share on revenue of $1.04 billion. In the same quarter a year earlier Neurocrine Biosciences reported $2.17 per share on revenue of $794.90 million. Neurocrine Biosciences last reported on July 31, 2026, posting $2.85 per share and beating the $1.65 consensus estimate. Neurocrine Biosciences has beaten the consensus EPS estimate in 3 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$1.91
Expected Revenue
$1.04 billion
Prior-Year EPS
$2.17
Prior-Year Revenue
$794.90 million
Expected EPS Growth
-12.0%
Expected Revenue Growth
+31.4%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$2.85 (Beat by +$1.20)
Last Quarter Revenue
$959.00 million
EPS Beat Rate
3 of last 8 quarters

Prepare for the Q3 2026 Call

Neurocrine Biosciences Q3 2026 Earnings FAQ

Neurocrine Biosciences (NASDAQ:NBIX) is estimated to report Q3 2026 earnings on Monday, November 2, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Neurocrine Biosciences' Q3 2026 earnings conference call is scheduled for Monday, November 2, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Neurocrine Biosciences to post earnings of $1.91 per share for Q3 2026.

The consensus revenue estimate for Neurocrine Biosciences is $1.04 billion for Q3 2026.

Neurocrine Biosciences Earnings Headlines

Neurocrine Biosciences' Vykat XR Sales Likely to Remain 'Flattish' Near Term, RBC Says
 |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/neurocrine-biosciences-apos-vykat-xr-162554230.html
Axsome Therapeutics (AXSM) vs. Neurocrine Biosciences (NBIX): Is Faster Growth Worth Paying More For?
 |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/axsome-therapeutics-axsm-vs-neurocrine-174211772.html
Ticker Revealed: Pre-IPO Access to "Next Elon Musk" Company
We’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.tc pixel
October 13 at 1:00 AM  |  Banyan Hill Publishing (Ad)
Why Neurocrine Biosciences (NBIX) is a top growth stock for the long term
October 13 at 1:13 PM  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/why-neurocrine-biosciences-nbix-is-a-top-growth-stock-for-the-long-term/ar-AA2e97jF
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results
October 12 at 4:01 PM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-conference-call-and-webcast-of-third-quarter-2026-financial-results-302906096.html
Scilex (NASDAQ:SCLX) & Neurocrine Biosciences (NASDAQ:NBIX) Financial Comparison
October 12 at 7:28 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31110216
See More Neurocrine Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Neurocrine Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Neurocrine Biosciences and other key companies, straight to your email.

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ:NBIX) is a biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and related disorders. The company is headquartered in San Diego, California, and conducts research through internal programs and collaborations with academic institutions and other pharmaceutical companies.

Neurocrine’s principal commercial product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor used to treat tardive dyskinesia and chorea associated with Huntington’s disease. The company also markets ONGENTYS (opicapone), an adjunctive treatment for “off” episodes in adults with Parkinson’s disease receiving levodopa and carbidopa. Its portfolio has also included therapies developed through partnerships, such as elagolix, which was commercialized by AbbVie for certain women’s health conditions.

Founded in 1992, Neurocrine has built its business around treatments for conditions with significant unmet medical needs. In 2024, the U.S. Food and Drug Administration approved Crenessity (crinecerfont) as an adjunctive treatment to glucocorticoid replacement therapy for adults and children with classic congenital adrenal hyperplasia. The company primarily serves the U.S. market while pursuing international commercialization through regional partners and license agreements.

Neurocrine is led by Chief Executive Officer Kyle Gano, who has held leadership positions with the company since joining in 2011.

View Neurocrine Biosciences Profile
Earnings Tools